Is Wall Street Turning on Amarin?

Today, Fool.com health-care analysts Brenton Flynn and David Williamson look at an unexpected downgrade of Amarin from Wedbush Securities. While Wedbush still believes the company makes for an attractive target, it's less optimistic that a Big Pharma buyout will happen as early as previously expected.

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 04, 2012, at 10:59 AM, skm1965 wrote:

    I thought analysts develop price targets based on Sales/Earnings ,DCF analysis--NOT Buyouts which are impossible to predict.

    Wedbush analyst Felt track record is very poor.

    3/24/2012-- Akira Felt rated

    AMRN,IDIX,HTWR,CRDC,ACHN as BUY

    THOR as Neutral

    HTWR,THOR -- his good calls

    IDIX,CRDC -down over 40%

    AMRN,ACHN--flat

    2 out of 6 good calls

    4 out of 6 bad calls

  • Report this Comment On October 04, 2012, at 11:09 AM, skm1965 wrote:

    Small co.are good at launching in USA.

    VERTEX vs.Merck for Hep.C

    Vertex gained 75% market share in 5 months.

    Amarin has hired PAUL HUFF as Chief Commercial Officer.

    He was responsible for Lovaza and Niaspan.

    He was hired by Reliant in Feb.2004 -and left after GSK took over in 2008.

    During his tenure as VP--marketing and business develop. Sales grew to 500mil.$ in 3 years from ZERO.

    GSK grew it to 900 mil$ from 500mil.$ from 2008-2011.

    Amarin has top CCO HUFF and can do a great job in USA.

    They need expertise in Overseas market.

    Huff was with ELI LILLY from 1988-2004-last position as VP Corp.Business Develop.

Add your comment.

DocumentId: 2043195, ~/Articles/ArticleHandler.aspx, 4/19/2014 5:34:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.


Advertisement